Drugs / N-acetylcystein
N-acetylcystein
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT02937376 | Feb → Jun 2023 | G6PD deficiency | University of Thessaly | Unknown | No outcome recorded |
| Phase 0 | NCT00337038 | Jun 2006 → Jul 2010 | essential hypertension, type 2 diabetes mellitus | Soroka University Medical Center | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00614679 | Oct 2006 → Dec 2008 | end stage renal failure | University of California, San Diego | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT01439828 | Feb 2012 | cannabis dependence, substance abuse | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01394497 | Dec 2006 → Jul 2009 | acute liver failure, hepatocellular carcinoma | Azienda Ospedaliera di Padova | Completed | Met primary |
| Phase 44 trials | ||||||
| Phase 4 | NCT02626494 | Mar 2015 → Mar 2017 | cocaine dependence | Psychiatric University Hospital, Zurich | Completed | No outcome recorded |
| Phase 4 | NCT01572597 | Jun 2011 → Dec 2012 | Helicobacter pylori infectious disease | Buddhist Tzu Chi General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00476736 | May 2007 | — | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00356954 | Feb 2005 → Apr 2006 | kidney failure | Seoul National University Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01327625 | Mar 2011 → Jun 2013 | graft versus host disease, transplant-related bronchiolitis obliterans | Asan Medical Center | Terminated | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT01820195 Comparator | Mar 2013 → Aug 2014 | chronic kidney disease | Imam Khomeini Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01741207 Comparator | Jan 2011 → Dec 2012 | acute myocardial infarction | Tehran University of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-acetyl cystein | “Group A - will receive 600-1200 mg N-acetyl cystein twice daily.” NCT00476736 ↗ |
| Known as | Fluimucil (Zambon, Italy) | “Fluimucil (Zambon, Italy)” NCT01394497 ↗ |
| Known as | N-acetylcysteine | “This study aims at testing for the impact of glutamatergic changes on drug craving in cocaine addiction, and to evaluate the effects of n-acetylcysteine (n-AC) on both...” NCT02626494 ↗2“Recent studies have shown that the antioxidant properties of N-acetylcysteine (NAC) may have cardioprotective effects in high doses, but-to the best of our knowledge-few...” PMID 29322434 ↗ Jun 2018 “N-acetylcysteine (NAC), an antioxidant/mucous modifier, has been shown to modify small airways, which mainly causes lung hyperinflation.” PMID 19447919 ↗ May 2009 |
| Known as | NAC | “This study aims at testing for the impact of glutamatergic changes on drug craving in cocaine addiction, and to evaluate the effects of n-acetylcysteine (n-AC) on both...” NCT02626494 ↗2“A trial of exercise before and after 4 weeks of N-acetyl cystein (NAC) supplementation.” NCT02937376 ↗ “N-Acetylcystein (NAC) is a drug known for its anti-oxidant and mucolytic activity.” NCT00476736 ↗ |
| Route | Oral | “p.O” NCT00337038 ↗ |